FDA Reviewing Epogen and Procrit Side Effects After Study Identifies Risk of Death
The FDA has issued an “Early Communication” about their ongoing safety review of a potential increased risk of death associated with Procrit and Epogen, which are used to treat anemia.
Epoetin alfa, which is the active pharmaceutical ingredient in both Procrit (marketed by Johnson & Johnson) and Epogen (marketed by Amgen), was recently linked to an increased risk of death in a German study where high doses of the drug were given following an ischemic stroke.
Both drugs are part of a class of medications known as erythropoiesis-stimulating agents (ESAs), which are approved to treat anemia that may develop in patients with chronic kidney failure, those with HIV who are on zidovudine and cancer patients who are on chemotherapy. Procrit and Epogen are also approved for patients undergoing major surgery (except heart surgery) to reduce the number of blood transfusions needed.
Did You Know?
Millions of Philips CPAP Machines Recalled
Philips DreamStation, CPAP and BiPAP machines sold in recent years may pose a risk of cancer, lung damage and other injuries.Learn More
Procrit and Epogen have been widely used off-label in recent years and drug makers have faced scrutiny surrounding their promotion of the drugs, which included payments to doctors for millions of dollars each year in return for prescribing the anemia drugs.
Last week Johnson & Johnson released a statement disclosing findings from a clinical study they funded in Germany to evaluate the impact of epoetin alfa on neurological function in patients who had suffered acute ischemic strokes. The study involved 522 patients who were given either a placebo or relatively high doses of epoetin alfa intravenously for three days.
Three months after the study began, data indicated that there were substantially more deaths among users of epoetin alfa than the placebo. Approximately 16% of the stroke patients given epoetin alfa died , compared with 9% who received the placebos. About half of the deaths in both groups occurred within the seven days after starting the therapy.
On September 23, 2008, the FDA released a statement known as an “Early Communication,” indicating that they were reviewing the data from this study to evaluate the potential connection between Procit and Epogen and increased mortality. An “Early Communication” does not mean that the regulatory agency has reached a conclusion about whether there is a cause and effect relationship, but is designed to communicate the FDA’s current analysis of data concerning the drug.
The FDA anticipates they will receive additional data needed to complete their review within the next several weeks. Once conclusions and recommendations are determined, the FDA will communicate those to the public.
Doctors have been urged to follow approved uses of Epogen and Procrit in correct dosages. Patients enrolled in other clinical studies of the drugs involving unapproved uses, such as for neuroprotection purposes, will need to be carefully monitored to see if the potential benefits of the drugs outweigh the risks involved.
VipinFebruary 28, 2012 at 8:01 am
i do not know of any braekroge firm that will allow that and i have traded through ameritrade, scottrade, etrade, and schwab..for their own reasons, they demand that an account be funded through either electronic transfer, personal check, or cashiers' check you can try drawing down on the cash limit of your credit card by way of one of their checks, deposit it, and then draw out of your account a [Show More]i do not know of any braekroge firm that will allow that and i have traded through ameritrade, scottrade, etrade, and schwab..for their own reasons, they demand that an account be funded through either electronic transfer, personal check, or cashiers' check you can try drawing down on the cash limit of your credit card by way of one of their checks, deposit it, and then draw out of your account a round about way but it would work just fineany way you look at it, it's a hassel
k wierzbickiFebruary 2, 2010 at 7:39 pm
My father-in law is on Procrit, also being treated for prostate cancer that has spread to his bones, his blood count is low this week, and is receiving blood transfusions right now..
CharlesOctober 20, 2009 at 1:37 pm
I have a patient who developed pure red cell aplasia (no red cells) after taking Procrit, with antibodies to Procrit, and requires a unit of blood each week. There are only 2 reported cases - does anyone know of others?
AdrianaJune 18, 2009 at 5:54 pm
I must say that I have been taking Epogen , Procrit for over close to seven years, due to my kidney problems that lead to severe anemia. I'm currently on dialysis now for a year, and worry about any serious side effects in the long-run. I am 39 years old and waiting on a new kidney.
"*" indicates required fields
More Top Stories
Bard claims two cases selected for the third and fourth bellwether trials are no longer representative of the litigation due to the plaintiffs' worsening injuries and need for additional surgeries due to their failed hernia mesh products.
More than 775 Exactech lawsuits have been filed in federal and state courts as parties work toward a plan for bellwether early test trials.
A federal judge has announced he will soon begin remanding 3M earplug lawsuits back to their originating districts for trials over claims of veteran hearing loss.